Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas E Feltner

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Psychopharmacology (Oxford, England)|February 12, 2010
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acidDouglas E Feltner, George Haig
Primary Care Companion to the Journal of Clinical Psychiatry|August 10, 2010
Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needsJonathan R T Davidson, Douglas E Feltner, Ashish Dugar
International Clinical Psychopharmacology|March 4, 2011
Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose studyDouglas E Feltner, Maria Liu-Dumaw, Edward Schweizer, et al.
The International Journal of Neuropsychopharmacology|September 10, 2009
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorderR Bruce Lydiard, Karl Rickels, Barry Herman, et al.
Journal of Clinical Psychopharmacology|March 2, 2005
Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosingRobert B Pohl, Douglas E Feltner, Ronald R Fieve, et al.
Drug and Alcohol Dependence|May 22, 2003
Incorporating the assessment of abuse liability into the drug discovery and development processRobert S Mansbach, Douglas E Feltner, Lisa H Gold, et al.
Biological Psychiatry|May 1, 2012
Vocal acoustic biomarkers of depression severity and treatment responseJames C Mundt, Adam P Vogel, Douglas E Feltner, et al.
The Journal of Clinical Psychiatry|February 9, 2012
An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHDSuzanne M Sutherland, Lenard A Adler, Crystal Chen, et al.
CNS Neuroscience & Therapeutics|February 21, 2009
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorderDouglas E Feltner, Jane Harness, Jerri Brock, et al.
British Journal of Clinical Pharmacology|August 22, 2009
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunitBrian Corrigan, Douglas E Feltner, Daniele Ouellet, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Psychopharmacology (Oxford, England)|February 12, 2010
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acidDouglas E Feltner, George Haig
Primary Care Companion to the Journal of Clinical Psychiatry|August 10, 2010
Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needsJonathan R T Davidson, Douglas E Feltner, Ashish Dugar
International Clinical Psychopharmacology|March 4, 2011
Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose studyDouglas E Feltner, Maria Liu-Dumaw, Edward Schweizer, et al.
The International Journal of Neuropsychopharmacology|September 10, 2009
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorderR Bruce Lydiard, Karl Rickels, Barry Herman, et al.
Journal of Clinical Psychopharmacology|March 2, 2005
Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosingRobert B Pohl, Douglas E Feltner, Ronald R Fieve, et al.
Drug and Alcohol Dependence|May 22, 2003
Incorporating the assessment of abuse liability into the drug discovery and development processRobert S Mansbach, Douglas E Feltner, Lisa H Gold, et al.
Biological Psychiatry|May 1, 2012
Vocal acoustic biomarkers of depression severity and treatment responseJames C Mundt, Adam P Vogel, Douglas E Feltner, et al.
The Journal of Clinical Psychiatry|February 9, 2012
An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHDSuzanne M Sutherland, Lenard A Adler, Crystal Chen, et al.
CNS Neuroscience & Therapeutics|February 21, 2009
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorderDouglas E Feltner, Jane Harness, Jerri Brock, et al.
British Journal of Clinical Pharmacology|August 22, 2009
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunitBrian Corrigan, Douglas E Feltner, Daniele Ouellet, et al.
Pageof 3